Li Ping
#176,989
Most Influential Person Now
Chinese geologist and earthquake engineer
Li Ping 's AcademicInfluence.com Rankings
Li Ping earth-sciences Degrees
Earth Sciences
#2918
World Rank
#3925
Historical Rank
Physical Geography
#207
World Rank
#243
Historical Rank
Li Ping engineering Degrees
Engineering
#8549
World Rank
#10116
Historical Rank
Earthquake Engineering
#14
World Rank
#15
Historical Rank
Applied Physics
#3661
World Rank
#3790
Historical Rank
Download Badge
Earth Sciences Engineering
Li Ping 's Degrees
- PhD Geology Peking University
Why Is Li Ping Influential?
(Suggest an Edit or Addition)According to Wikipedia, Li Ping was a Chinese geologist and earthquake engineer. He was an academician of the Chinese Academy of Engineering. Biography Li Ping was born on 20 March 1924 in Dawu County, Hubei, Republic of China. He entered National Central University in 1943, and became a faculty member after graduating in 1947.
Li Ping 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A safe and potent anti-CD19 CAR T cell therapy (2019) (255)
- Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma (2019) (90)
- A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type (2013) (67)
- The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages (2017) (58)
- Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin (2015) (47)
- Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades (2020) (39)
- Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome (2016) (31)
- Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma (2018) (27)
- The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma (2018) (21)
- ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma (2019) (20)
- Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma (2015) (19)
- Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients (2016) (18)
- Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era? (2013) (16)
- Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells (2014) (16)
- Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel. (2014) (14)
- Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas (2018) (12)
- The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma (2018) (10)
- Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry (2019) (9)
- Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study (2019) (9)
- EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP (2017) (9)
- PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma (2017) (8)
- TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP (2017) (8)
- 415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas (2015) (8)
- PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity (2018) (8)
- Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China (2021) (7)
- The clinical outcomes of fresh versus cryopreserved CD19-Directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients. (2020) (6)
- Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma (2014) (6)
- Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies (2021) (6)
- Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma (2015) (6)
- Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. (2013) (5)
- Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab (2014) (5)
- Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies (2021) (4)
- Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation (2019) (4)
- Cerebrospinal Fluid Proteins Identification Facilitates the Differential Diagnosis of Central Nervous System Diffuse Large B Cell Lymphoma (2017) (4)
- [Clinical value of flow cytometry in assessing bone marrow involvement of non-Hodgkin's lymphoma]. (2014) (4)
- A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma (2021) (3)
- CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (2018) (3)
- High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China (2020) (3)
- [Prognostic value of 18F-FDG PET-CT in Hodgkin lymphoma]. (2014) (3)
- Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma (2020) (2)
- A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma (2022) (2)
- [Expression and prognostic value of COX- 2, p16(INK4A) and p53 in patients with classical Hodgkin lymphoma]. (2015) (2)
- Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients (2020) (2)
- [Non-upper aerodigestive tract NK/T- cell lymphoma: an analysis of clinical features and survival from a single center in China]. (2015) (2)
- Prognostic role of serum miRNA-16 in primary gastric lymphoma. (2018) (2)
- Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma (2021) (2)
- Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation. (2017) (2)
- Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma (2022) (2)
- Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (2018) (1)
- Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients (2020) (1)
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma (2019) (1)
- Characterization of the Novel Insecticidal Crystal Protein Cyt3Aa1 from Bacillus thuringiensis TD516 (2020) (1)
- Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma (2014) (1)
- Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial (2022) (1)
- PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity (2018) (0)
- Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab (2014) (0)
- A safe and potent anti-CD19 CAR T cell therapy (2019) (0)
- Application progress of autologous stem cell transplantation in lymphoma treatment (2020) (0)
- [Prognostic value of interim and post-therapy 18F-FDG PET-CT in patients with T-cell lymphomas]. (2014) (0)
- TREATMENT STRATEGIES AND PROGNOSTIC FACTORS OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY OF 303 CASES FROM CHINA LYMPHOMA PATIENT REGISTRY (2017) (0)
- Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma (2019) (0)
- Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China. (2022) (0)
- [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]. (2016) (0)
- [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma]. (2014) (0)
- Clinical analysis of 13 cases with Burkitt lymphoma or Burkitt-like lymphoma (2010) (0)
- Diagnosis and treatment of mucosa-associated lymphoid tissue lymphoma (2009) (0)
- A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation (2018) (0)
- Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study (2023) (0)
- CLINICAL FEATURES AND PROGNOSES OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 139 CHINESE CASES WITH IMMUNOPHENOTYPING FROM CLAP (2017) (0)
- Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells (2014) (0)
- CAMRELIZUMAB COMBINED WITH GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (2021) (0)
- CMAR_A_324543 6731..6741 (2021) (0)
- EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP (2017) (0)
- Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19 (2020) (0)
- Hepatitis B virus infection status is not associated with poor prognosis in classical Hodgkin lymphoma patients. (2019) (0)
- TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP (2017) (0)
- ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma (2019) (0)
- Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin’s lymphoma (2019) (0)
- THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB EXERTS IMMUNOMODULATORY ACTIVITY TOWARDS TUMOR‐INFILTRATING MACROPHAGES (2017) (0)
- The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma (2022) (0)
- Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients (2020) (0)
- Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study (2023) (0)
- Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies (2021) (0)
- 893MO An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma (2020) (0)
This paper list is powered by the following services:
Other Resources About Li Ping
What Schools Are Affiliated With Li Ping ?
Li Ping is affiliated with the following schools:
